Semler Scientific, Inc. Provides Earnings Guidance for Second Half and Full Year Ended December 31, 2022
August 02, 2022 at 04:01 pm EDT
Share
Semler Scientific, Inc. provided earnings guidance for second half and full year ended December 31, 2022. For the period, The company expects revenue will range from $29.2 million to $31.2 million representing a growth rate of 14% to 21% compared to the second half of 2021.
For the full year, The company expects Annual revenue will range from $58.0 million to $60.0 million, representing a growth rate of 9% to 14%.
Semler Scientific, Inc. develops, manufactures, and markets products and services that assist in evaluating and treating chronic diseases. The Company provides technology solutions to healthcare providers. The Company's flagship product, QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patientâs vascular condition, including assessments of patients who have vascular disease. QuantaFlo features a sensor clamp that is placed on the toe or finger. Infrared light emitted from the clamp on the dorsal surface of the digit is scattered and reflected by the red blood cells coursing through the area of illumination. Returning light is sensed by the sensor. A blood flow waveform is instantaneously constructed by its proprietary software algorithm. Its customers for QuantaFlo include insurance plans, physician groups, risk assessment groups, hospitals and retailers.
SEMLER SCIENTIFIC, INC. 
